Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 versus placebo after complete resection of non-small cell lung cancer
RBR-3j2xxqPhase 3Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Mar 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab with Placebo (2 arms). Started Mar 2015; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on RBR-3j2xxq.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-3j2xxq.